Skip to main content
Premium Trial:

Request an Annual Quote

CDI Labs HuScan and VirScan

CDI Laboratories' Antygen Division, which provides contract research for R&D in the therapeutic and diagnostic space, has launched two biomarker discovery assays, HuScan and VirScan. HuScan detects antibodies against the entire human proteome via long peptides on the surface of bacteriophages, antibody pulldown, and sequencing readouts. VirScan detect antibodies against the proteomes of every viral strain known to infect humans in the same manner. Both assays represent the first commercial use of PhIP-seq technology, the company said.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.